Dr. Ramnaraign on Current Treatment Guidelines for First-Line Metastatic RCC

Brian Ramnaraign, MD, assistant professor of medicine, Division of Hematology and Oncology, University of Florida College of Medicine, discusses current first-line treatment guidelines for patients with metastatic renal cell carcinoma (RCC). 

Currently, many first-line treatment options are available for use in this patient population, according to Ramnaraign. When choosing among these approaches, is important to determine whether a patient has favorable-, intermediate-, or poor-risk disease, Ramnaraign says. 

There are 3 category 1 National Comprehensive Cancer Network recommendations for patients with favorable-risk disease, and 4 recommendations for those with intermediate- and poor-risk disease, Ramnaraign explains.

For patients with poor- or immediate-risk disease, possible treatment strategies include dual immunotherapy regimens or immunotherapies in combination with TKIs. For those with favorable-risk disease, immunotherapy/TKI combinations are often utilized, Ramnaraign concludes.